Kang LI,Tong ZHANG,Jing SONG,Lanlan XU,Qi LIU,Hao PENG
申请号：
US15802093
公开号：
US20180111995A1
申请日:
2017.11.02
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
